Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study

J. H. Tabibian, E. Weeding, R. A. Jorgensen, J. L. Petz, J. C. Keach, J. A. Talwalkar, K. D. Lindor

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Background Emerging data suggest that oral antibiotics may have therapeutic effects in primary sclerosing cholangitis (PSC), but published studies are limited. Aims To investigate the safety and efficacy of oral vancomycin and metronidazole in patients with PSC. Methods Thirty-five patients with PSC were randomised in a double-blind manner into four groups: vancomycin 125 mg or 250 mg four times/day, or metronidazole 250 mg or 500 mg three times/day for 12 weeks. The primary endpoint was decrease in alkaline phosphatase (ALK) at 12 weeks. Secondary end points included serum bilirubin and Mayo PSC risk score; pruritus; and adverse effects (AEs). Nonparametric tests were used for analysis. Results The primary endpoint was reached in the low-dose (-43% change in ALK, P = 0.03) and high-dose (-40%, P = 0.02) vancomycin groups, with two patients in the former experiencing ALK normalisation. Bilirubin decreased significantly in the low-dose metronidazole group (-20%, P = 0.03) and trended towards significance in the low-dose vancomycin group (-33%, P = 0.06). Mayo PSC risk score decreased significantly in the low-dose vancomycin (-0.55, P = 0.02) and low-dose metronidazole group (-0.16, P = 0.03). Pruritus decreased significantly in the high-dose metronidazole group (-3.4, P = 0.03). AEs led to medication discontinuation in six patients, four of whom were receiving metronidazole. Conclusions Both vancomycin and metronidazole demonstrated efficacy; however, only patients in the vancomycin groups reached the primary endpoint, and with less adverse effects. Larger, longer-term studies are needed to further examine the safety and efficacy of antibiotics as a potential treatment for patients with primary sclerosing cholangitis (clinicaltrials.gov NCT01085760).

Original languageEnglish (US)
Pages (from-to)604-612
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume37
Issue number6
DOIs
StatePublished - Mar 2013

Fingerprint

Sclerosing Cholangitis
Metronidazole
Vancomycin
Randomized Controlled Trials
Alkaline Phosphatase
Pruritus
Bilirubin
Anti-Bacterial Agents
Safety
Therapeutic Uses
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Tabibian, J. H., Weeding, E., Jorgensen, R. A., Petz, J. L., Keach, J. C., Talwalkar, J. A., & Lindor, K. D. (2013). Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study. Alimentary Pharmacology and Therapeutics, 37(6), 604-612. https://doi.org/10.1111/apt.12232

Randomised clinical trial : Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study. / Tabibian, J. H.; Weeding, E.; Jorgensen, R. A.; Petz, J. L.; Keach, J. C.; Talwalkar, J. A.; Lindor, K. D.

In: Alimentary Pharmacology and Therapeutics, Vol. 37, No. 6, 03.2013, p. 604-612.

Research output: Contribution to journalArticle

Tabibian, JH, Weeding, E, Jorgensen, RA, Petz, JL, Keach, JC, Talwalkar, JA & Lindor, KD 2013, 'Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study', Alimentary Pharmacology and Therapeutics, vol. 37, no. 6, pp. 604-612. https://doi.org/10.1111/apt.12232
Tabibian, J. H. ; Weeding, E. ; Jorgensen, R. A. ; Petz, J. L. ; Keach, J. C. ; Talwalkar, J. A. ; Lindor, K. D. / Randomised clinical trial : Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study. In: Alimentary Pharmacology and Therapeutics. 2013 ; Vol. 37, No. 6. pp. 604-612.
@article{6d87bda165e04d5e926a1bfdb4ed57de,
title = "Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study",
abstract = "Background Emerging data suggest that oral antibiotics may have therapeutic effects in primary sclerosing cholangitis (PSC), but published studies are limited. Aims To investigate the safety and efficacy of oral vancomycin and metronidazole in patients with PSC. Methods Thirty-five patients with PSC were randomised in a double-blind manner into four groups: vancomycin 125 mg or 250 mg four times/day, or metronidazole 250 mg or 500 mg three times/day for 12 weeks. The primary endpoint was decrease in alkaline phosphatase (ALK) at 12 weeks. Secondary end points included serum bilirubin and Mayo PSC risk score; pruritus; and adverse effects (AEs). Nonparametric tests were used for analysis. Results The primary endpoint was reached in the low-dose (-43{\%} change in ALK, P = 0.03) and high-dose (-40{\%}, P = 0.02) vancomycin groups, with two patients in the former experiencing ALK normalisation. Bilirubin decreased significantly in the low-dose metronidazole group (-20{\%}, P = 0.03) and trended towards significance in the low-dose vancomycin group (-33{\%}, P = 0.06). Mayo PSC risk score decreased significantly in the low-dose vancomycin (-0.55, P = 0.02) and low-dose metronidazole group (-0.16, P = 0.03). Pruritus decreased significantly in the high-dose metronidazole group (-3.4, P = 0.03). AEs led to medication discontinuation in six patients, four of whom were receiving metronidazole. Conclusions Both vancomycin and metronidazole demonstrated efficacy; however, only patients in the vancomycin groups reached the primary endpoint, and with less adverse effects. Larger, longer-term studies are needed to further examine the safety and efficacy of antibiotics as a potential treatment for patients with primary sclerosing cholangitis (clinicaltrials.gov NCT01085760).",
author = "Tabibian, {J. H.} and E. Weeding and Jorgensen, {R. A.} and Petz, {J. L.} and Keach, {J. C.} and Talwalkar, {J. A.} and Lindor, {K. D.}",
year = "2013",
month = "3",
doi = "10.1111/apt.12232",
language = "English (US)",
volume = "37",
pages = "604--612",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Randomised clinical trial

T2 - Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study

AU - Tabibian, J. H.

AU - Weeding, E.

AU - Jorgensen, R. A.

AU - Petz, J. L.

AU - Keach, J. C.

AU - Talwalkar, J. A.

AU - Lindor, K. D.

PY - 2013/3

Y1 - 2013/3

N2 - Background Emerging data suggest that oral antibiotics may have therapeutic effects in primary sclerosing cholangitis (PSC), but published studies are limited. Aims To investigate the safety and efficacy of oral vancomycin and metronidazole in patients with PSC. Methods Thirty-five patients with PSC were randomised in a double-blind manner into four groups: vancomycin 125 mg or 250 mg four times/day, or metronidazole 250 mg or 500 mg three times/day for 12 weeks. The primary endpoint was decrease in alkaline phosphatase (ALK) at 12 weeks. Secondary end points included serum bilirubin and Mayo PSC risk score; pruritus; and adverse effects (AEs). Nonparametric tests were used for analysis. Results The primary endpoint was reached in the low-dose (-43% change in ALK, P = 0.03) and high-dose (-40%, P = 0.02) vancomycin groups, with two patients in the former experiencing ALK normalisation. Bilirubin decreased significantly in the low-dose metronidazole group (-20%, P = 0.03) and trended towards significance in the low-dose vancomycin group (-33%, P = 0.06). Mayo PSC risk score decreased significantly in the low-dose vancomycin (-0.55, P = 0.02) and low-dose metronidazole group (-0.16, P = 0.03). Pruritus decreased significantly in the high-dose metronidazole group (-3.4, P = 0.03). AEs led to medication discontinuation in six patients, four of whom were receiving metronidazole. Conclusions Both vancomycin and metronidazole demonstrated efficacy; however, only patients in the vancomycin groups reached the primary endpoint, and with less adverse effects. Larger, longer-term studies are needed to further examine the safety and efficacy of antibiotics as a potential treatment for patients with primary sclerosing cholangitis (clinicaltrials.gov NCT01085760).

AB - Background Emerging data suggest that oral antibiotics may have therapeutic effects in primary sclerosing cholangitis (PSC), but published studies are limited. Aims To investigate the safety and efficacy of oral vancomycin and metronidazole in patients with PSC. Methods Thirty-five patients with PSC were randomised in a double-blind manner into four groups: vancomycin 125 mg or 250 mg four times/day, or metronidazole 250 mg or 500 mg three times/day for 12 weeks. The primary endpoint was decrease in alkaline phosphatase (ALK) at 12 weeks. Secondary end points included serum bilirubin and Mayo PSC risk score; pruritus; and adverse effects (AEs). Nonparametric tests were used for analysis. Results The primary endpoint was reached in the low-dose (-43% change in ALK, P = 0.03) and high-dose (-40%, P = 0.02) vancomycin groups, with two patients in the former experiencing ALK normalisation. Bilirubin decreased significantly in the low-dose metronidazole group (-20%, P = 0.03) and trended towards significance in the low-dose vancomycin group (-33%, P = 0.06). Mayo PSC risk score decreased significantly in the low-dose vancomycin (-0.55, P = 0.02) and low-dose metronidazole group (-0.16, P = 0.03). Pruritus decreased significantly in the high-dose metronidazole group (-3.4, P = 0.03). AEs led to medication discontinuation in six patients, four of whom were receiving metronidazole. Conclusions Both vancomycin and metronidazole demonstrated efficacy; however, only patients in the vancomycin groups reached the primary endpoint, and with less adverse effects. Larger, longer-term studies are needed to further examine the safety and efficacy of antibiotics as a potential treatment for patients with primary sclerosing cholangitis (clinicaltrials.gov NCT01085760).

UR - http://www.scopus.com/inward/record.url?scp=84874117027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874117027&partnerID=8YFLogxK

U2 - 10.1111/apt.12232

DO - 10.1111/apt.12232

M3 - Article

C2 - 23384404

AN - SCOPUS:84874117027

VL - 37

SP - 604

EP - 612

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -